Bites of Bio

Non-HDL cholesterol on your lipid panel: what it is and how it compares with your LDL

Share



Laboratory professional holding a blood sample tube in a clinical testing laboratory.
Credit: Pexels

Non-high-density lipoprotein cholesterol (non-HDL-C) is recommended as a routine part of cardiovascular risk assessment in the 2026 American College of Cardiology and American Heart Association dyslipidemia guideline, because it captures cholesterol carried by several artery-plaque-forming lipoproteins rather than low-density lipoprotein (LDL) alone. A November 2026 cohort study in PLOS Medicine, involving 185,237 people who started statins for primary prevention, also found that lower achieved non-HDL-C was associated with fewer major cardiovascular events, although the observational design cannot establish the effect of lowering this particular measurement independently.

Non-HDL cholesterol is calculated from two numbers on a standard lipid panel

A routine lipid panel usually reports total cholesterol, high-density lipoprotein cholesterol (HDL-C), LDL cholesterol (LDL-C), and triglycerides. HDL-C refers to cholesterol carried by particles that participate in cholesterol transport away from tissues, but calling all HDL “good” and all other cholesterol “bad” oversimplifies lipoprotein biology.

Non-HDL-C is calculated with a straightforward subtraction: total cholesterol minus HDL cholesterol. If total cholesterol is 210 milligrams per deciliter (mg/dL) and HDL-C is 50 mg/dL, non-HDL-C is 160 mg/dL. This is an illustrative calculation, not an individualized diagnosis or a recommendation to start treatment.

Unlike LDL-C, non-HDL-C includes the cholesterol carried by a broader group of apolipoprotein B-containing lipoproteins. Those include LDL, very-low-density lipoproteins (VLDL), intermediate-density lipoproteins, and remnant particles. Lipoprotein(a), another risk-associated particle, also contributes to the measurement. Each can transport cholesterol that may contribute to atherosclerotic plaque formation.

The calculation does not measure the number of these particles, nor does it provide separate concentrations for LDL and remnants. It gives clinicians an aggregate cholesterol-mass measure that is available from almost every standard lipid panel.

LDL cholesterol can look acceptable while other atherogenic cholesterol remains elevated

LDL-C remains a central measure for risk assessment and cholesterol-lowering treatment. However, LDL-C alone does not capture all of the cholesterol carried by triglyceride-rich particles. This distinction may be especially relevant when triglycerides are elevated, as can occur alongside insulin resistance and type 2 diabetes.

For example, consider a hypothetical lipid panel with total cholesterol of 200 mg/dL, HDL-C of 40 mg/dL, LDL-C of 100 mg/dL, and triglycerides of 250 mg/dL. Non-HDL-C would be 160 mg/dL, which is substantially higher than the LDL-C figure because it incorporates cholesterol outside the LDL fraction. The numbers are illustrative; the actual relationship depends on how LDL-C is estimated and the composition of circulating lipoproteins.

Patients who want to understand the separate concept of lipoprotein particle number can read our earlier analysis, whether apolipoprotein B (ApoB) predicts heart disease risk better than LDL cholesterol. ApoB testing can provide additional information, but it is not simply another name for non-HDL-C. Non-HDL-C measures cholesterol mass, while ApoB concentration estimates atherogenic particle burden.

The 2026 US guideline explicitly recommends reporting non-HDL cholesterol

The 2026 ACC/AHA multisociety guideline recommends that laboratories report non-HDL-C from routine lipid profiles for atherosclerotic cardiovascular disease (ASCVD) risk assessment and for decisions about initiating and monitoring lipid-lowering treatment. It also favors the Martin/Hopkins or Sampson/National Institutes of Health equations over the older Friedewald formula when estimating LDL-C.

The guideline reintroduces LDL-C and non-HDL-C treatment goals, with more intensive targets for people at higher cardiovascular risk. For some adults starting lipid-lowering treatment at borderline or intermediate primary-prevention risk, a reasonable goal is LDL-C below 100 mg/dL and non-HDL-C below 130 mg/dL. In higher-risk groups, recommended goals are lower.

Those figures should not be applied indiscriminately. Age, prior cardiovascular events, diabetes, blood pressure, smoking, family history, kidney health, and the estimated risk of future disease influence the treatment discussion. For very-high-risk patients with established ASCVD, the guideline includes LDL-C below 55 mg/dL and non-HDL-C below 85 mg/dL among its recommended goals.

That risk-based approach complements our reporting on silent atherosclerotic plaque in younger adults, which explains why clinical risk cannot be reduced to whether someone feels well or has a single reassuring laboratory result.

A 185,237-person study linked lower achieved non-HDL cholesterol to fewer cardiovascular events

In research published November 3, 2026, in PLOS Medicine, Joseph Edgar Blais and colleagues analyzed electronic health records from Hong Kong, New Zealand, and the United Kingdom. The study included 185,237 adults who began statins between 2007 and 2012 to prevent a first cardiovascular event. People with existing atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease were excluded from the study population.

Researchers evaluated LDL-C and non-HDL-C concentrations measured within two years of starting statin treatment, then examined subsequent major adverse cardiovascular events and mortality. The analysis accounted for measured characteristics including age, sex, hypertension, diabetes, obesity, smoking, selected comorbidities, and medication use.

Lower non-HDL-C levels were associated with lower rates of major cardiovascular events. As one comparison, the adjusted hazard ratio for people with non-HDL-C of 2.6–3.3 millimoles per liter (approximately 101–128 mg/dL), versus at least 3.4 millimoles per liter (approximately 131 mg/dL), was 0.75 (95% confidence interval, 0.72–0.79). That corresponds to a 25% lower relative hazard in this observational comparison, not a proven 25% benefit caused by achieving that specific level.

Very low achieved LDL-C and non-HDL-C were not clearly linked to higher all-cause mortality after adjustment, although the authors noted uncertainty at the lowest levels and differences across geographic cohorts. The analysis supports the relevance of these lipid markers in people taking statins, but cannot establish that targeting non-HDL-C rather than LDL-C would produce better outcomes in a randomized comparison.

What the study cannot establish

This was not a randomized trial assigning people to distinct LDL-C or non-HDL-C goals. Treatment intensity and follow-up testing may have differed according to underlying cardiovascular risk, leaving room for confounding by indication and other unmeasured factors.

The researchers included only people who survived to the measurement point and had follow-up lipid values. That selection limits how directly the findings apply to everyone beginning statin therapy. Differences among the Hong Kong, New Zealand, and UK datasets also reduced precision for some results. Several authors disclosed relationships with pharmaceutical and healthcare companies outside the submitted work, while the stated graduate research award funders had no role in conducting or reporting the study.

The results are consistent with the wider evidence supporting lipid reduction, including trials showing lower cardiovascular event rates when LDL-C is reduced. Yet readers should not interpret an observational association between an achieved lipid concentration and later events as proof that a separate laboratory target independently causes the reduction.

Non-HDL cholesterol adds context, but it does not replace a cardiovascular risk assessment

For someone reviewing routine blood work, the first step is to identify total cholesterol and HDL-C and subtract the latter from the former. The result can be compared with the non-HDL-C value already reported by the laboratory. There is usually no reason to order an additional blood draw merely to calculate it.

The next question is not whether non-HDL-C is “good” or “bad” in isolation, but whether it agrees with LDL-C and whether either value is appropriate for the person’s level of risk. Elevated triglycerides, diabetes, established cardiovascular disease, or unexpectedly discordant results may prompt a clinician to examine ApoB, lipoprotein(a), or other factors. Decisions about starting, continuing, or intensifying statins also require clinical context, as discussed in our article on statin continuation after age 75.

Non-HDL-C offers a practical advantage: it broadens the information available from a standard lipid panel without adding another test. The 2026 guideline makes that value explicit, while the new international cohort adds evidence that achieved non-HDL-C tracks with cardiovascular outcomes during statin treatment.

References

  1. Blumenthal RS, et al. 2026 ACC/AHA multisociety guideline on the management of dyslipidemia. Circulation. Published March 13, 2026. DOI: 10.1161/CIR.0000000000001423.
  2. Blais JE, et al. Risk of cardiovascular events and mortality associated with LDL and non-HDL cholesterol levels after statin initiation for primary prevention: a multiregional cohort study. PLOS Medicine. 2026;23(11):e1005012. DOI: 10.1371/journal.pmed.1005012.
  3. Byrne P, et al. The association between remnant cholesterol and cardiovascular events: a systematic review and meta-regression. Journal of Clinical Lipidology. 2026;20(7):1339–1351. DOI: 10.1016/j.jacl.2026.03.026.

Leave a Comment

Your email address will not be published. Required fields are marked *